US-based contract development and manufacturing organization (CDMO) Cambrex has reached an agreement with Eli Lilly & Co., (NYSE: LLY), to enhance the clinical development capabilities for the US giant’s biotech collaborators. This partnership aims to provide a comprehensive suite of services to support early-stage biotech innovation.
Cambrex’s Role in Lilly Catalyze360-ExploR&D
Cambrex will collaborate with Lilly Catalyze360-ExploR&D, which is Eli Lilly’s early external innovation and collaboration arm. Through this collaboration, Cambrex will offer drug substance, drug product, analytical service labs, and R&D expertise to Lilly Catalyze360 biotech collaborators. The partnership focuses on providing a robust foundation for biotech companies to advance their drug development pipelines.
Cambrex’s Longmont Facility and Services
Cambrex’s facility in Longmont is specialized in the early development of investigational new drugs. The facility covers the full spectrum from process development and drug substance manufacturing to formulation development and drug product manufacturing, including capacities for both non-GMP and cGMP production. Additionally, the site offers full analytical development and cGMP testing support, ensuring that biotech collaborators have access to the necessary resources for successful drug development.-Fineline Info & Tech
